Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Clinical Trials LymphomaBoston

Lymphoma Clinical Trials in Boston

Find 559 clinical trials for lymphoma near Boston, Massachusetts. Connect with research centers in your area.

All Lymphoma trials nationwide All trials in Boston

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 321-340 of 559 trials

Active not recruitingComparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic LeukemiaThis phase II trial compares the combination of inotuzumab ozogamicin and low intensity chemotherapy and blinatumomab to the usual chemotherapy with blinatumomab in treating…NCT05303792·Birmingham, Alabama and 71 others

Lymphoma Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

TerminatedRituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's LymphomaRATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.NCT00110149·Boston, Massachusetts and 2 others

WithdrawnStudy to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell LymphomaThis is a Phase 1b/2 randomized study of Iberdomide (CC-220) added to 3 different combination regimens (polatuzumab vedotin plus rituximab (Cohort A), tafasitamab (Cohort B)…NCT04882163·Boston, Massachusetts and 26 others

CompletedCT-011 MAb in DLBCL Patients Following ASCTAutologous peripheral blood stem cell transplantation combined with high dose chemotherapy is the treatment of choice given to patients with diffuse large-B cell lymphoma (DLBCL)…NCT00532259·La Jolla, California and 26 others

CompletedStudy to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood CancerThis study will evaluate the effectiveness of fostamatinib (200 mg twice a day) in patients with worsening or unmanageable lymphoma with a specific type of lymphoma called Diffuse…NCT01499303·Huntsville, Alabama and 20 others

CompletedA Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell LymphomaThe purpose of this study is to evaluate if ibrutinib administered in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) improves the…NCT01855750·Tucson, Arizona and 200 others

UnknownCombination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaRATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.NCT00053105·Tucson, Arizona and 6 others

Active not recruitingSelinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)A multicenter, open-label Phase 2b study of selinexor (KPT-330) in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have no therapeutic…NCT02227251·Tucson, Arizona and 174 others

CompletedA Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against DoxorubicinThe purpose of this study is to compare the standard CHOP-R regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Rituximab to CPOP-R (same regimen, but…NCT00268853·Concord, California and 74 others

TerminatedA Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malignancies.NCT04035434·Los Angeles, California and 32 others

UnknownCare Planning for a Loved One With Dementia: Knowledge, Preparing for Decisions, and EmotionsThe overall objective of this study is to compare knowledge, decisional conflict, preferences, and caregiver burden over time caregivers of Alzheimer's Disease and Related…NCT05165186·Boston, Massachusetts

CompletedA Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin LymphomaThis was a Phase 2 clinical trial to evaluate the safety and efficacy of duvelisib as a monotherapy in participants with indolent non-Hodgkin lymphoma (iNHL) (follicular lymphoma…NCT01882803·Los Angeles, California and 68 others

CompletedA Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDSThe purpose of the study is to identify the maximum tolerated dose (MTD) of JNJ-64619178 in participants with relapsed/refractory B cell non-Hodgkin lymphoma (NHL) or advanced…NCT03573310·Sarasota, Florida and 17 others

CompletedA Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCC-99282-CLL-001 study is a Phase IB dose escalation and expansion clinical study of CC-99282 administered in combination with Obinutuzumab in subjects with relapsed or refractory…NCT04434196·Boston, Massachusetts and 14 others

Active not recruitingBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK…NCT02568267·Phoenix, Arizona and 119 others

TerminatedLong-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.A long-term follow-up study to assess safety and efficacy in patients previously treated with Mustang Bio chimeric antigen receptor (CAR)-T cell investigational products.NCT05645744·Orange, California and 4 others

TerminatedPhase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or LymphomaThe purpose of this study is to assess the safety and tolerability of the investigational anticancer drug DCR-MYC.NCT02110563·Stanford, California and 5 others

AvailableExpanded Access Program for OOS Obe-celThe purpose of this program is to provide access to obe-cel treatment for adult patients with ALL who have undergone leukapheresis and had obe-cel manufactured from their blood…NCT06799221·Gilbert, Arizona and 31 others

CompletedDose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic LeukaemiaThe study is in two parts: a dose escalation then a safety dose expansion.NCT02746952·Boston, Massachusetts and 8 others

CompletedA Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's LymphomaThis is an open-label, multicenter, Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0980 administered to patients with…NCT00854152·Chicago, Illinois and 4 others

PreviousPage 17 of 28Next

Other Conditions in Boston

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia